Doctors and nurses are used to seeing and hearing negative trials
(there are plenty of negative or inconclusive pharma studies).
Ben Goldacre's talk at the New York City Skeptics Society, where he expressed his concern about pharma companies hiding negative trial
2008 Sep 25;359:1343-56), SEAS was a negative trial
Panelists at the meeting said they were not comfortable drawing any conclusions from analyses of patient subgroups in a negative trial
was already growing at a rate of 109% per year, but the publicity of this negative trial
increased growth by an additional 46% in the week immediately following the publication of the negative HRT study.
Since this was a negative trial
(showing no difference between the treatment and control groups), it is important that the study was adequately powered to not miss a true difference.
For example, the completion of the Company's BRITE trial could be delayed and/or the trial could be unsuccessful as a result of various factors including delays in patient enrollment, lower than anticipated retention rates for patients in the trial, negative trial
outcomes and the failure of the trial to establish the predictive accuracy of the Company's brain assessment technology in predicting the effectiveness of antidepressant medications.
For example, the completion of one or both of the studies could be delayed and/or either trial could be unsuccessful as a result of various factors including delays in patient enrollment, lower than anticipated retention rates for patients in the trial, negative trial
outcomes and the failure of one or both of the trials to adequately assess the impact of anesthesia management techniques on patient outcomes.
In the wake of yet another negative trial
, Pfizer has discontinued research on bapineuzumab, a monoclonal antibody designed to target amyloid beta plaques in the brains of patients with Alzheimer's disease.
In terms of primary analysis and primary end point, this is a negative trial
Within the atypical antipsychotic class, there has been only one positive trial for risperidone (Risperdal) and one negative trial
The new EVEREST analysis contains an important message for clinical trialists: Using the signs and symptoms of congestion as a key target for treatment during hospitalization as well as the standard end point in acute heart failure studies, as has been common until now, is a recipe for a negative trial